All patients received continuous definitive radiotherapy: 177/198 (89.4%) patients

were treated with two-dimensional radiotherapy (2D-RT) and 21/198 (10.6%) patients received intensity-modulated radiotherapy (IMRT). Total dose delivered to the primary tumor site was 64-80 Gy, with RG 7204 a mean of 70.85 Gy (standard deviation, SD: ± 4.27 Gy) and a median of 70 Gy respectively. Dose for positive lymph node was 56-70 Gy, with a mean of 63.87 Gy (SD: ± 3.93 Gy) and a median of 64 Gy respectively. The prophylactic dose was 50-56 Gy. One hundred and thirty-eight patients received platinum-based chemotherapy: 72 patients received neoadjuvant chemotherapy, 100 patients received concurrent

chemotherapy and 11 patients received adjuvant chemotherapy. The institutional guidelines for NPC during this research period recommended no chemotherapy for T1 -2N0M0 (the AJCC staging system 2002 clinical classification, the sixth edition) patients, whose diseases were classified as stage I and stage II with no enlarged lymph nodes. However, concurrent chemoradiotherapy was required for stage II disease with positive lymph nodes and concurrent chemoradiotherapy Enzalutamide mouse with or without neoadjuvant/adjuvant chemotherapy was necessary for stage III to IVa-b patients. Neoadjuvant chemotherapy consisted of two cycles of cisplatin (80 mg/m2) by intravenous drip and 5-fluorouracil (5-Fu) (4 g/m2) by continuous intravenous infusion for 120 hours every three weeks. Concurrent chemotherapy

consisted of two to three cycles of cisplatin (80 mg/m2) by intravenous drip on weeks 1, 4 and/or 7 during radiotherapy. Adjuvant chemotherapy consisted of cisplatin (80 mg/m2) by intravenous drip and 5-Fu (4 g/m2) continuous intravenous infusion for 120 hours every four weeks. Patients were advised to attend follow-up visit every three months for the first three years, every six months for the fourth and fifth years, and every year thereafter. The primary end point was overall survival (OS), and the secondary end points were distant Dapagliflozin metastasis-free survival (DMFS), progression-free survival (PFS) and locoregional failure-free survival (LRFS). The up-mentioned end points were defined as followed: OS, the time from finishing radiotherapy to the date of death or the latest visit date if patients were still alive; DMFS, the time from finishing radiotherapy to the date of distant metastasis or the latest visit date when censored; LRFS, the time from finishing radiotherapy to the date of failure in nasopharynx and/or cervical lymph nodes or the latest visit date when censored; PFS, the time from finishing radiotherapy to the date of relapse at any site or the latest visit date when censored.